NAD+ Decline With Age: What the Research Shows

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell. It is essential for mitochondrial energy production, DNA repair, sirtuin activation, and hundreds of other enzymatic reactions. Over the past decade, a growing body of peer-reviewed research has demonstrated that NAD+ levels decline significantly with age — and that this decline is closely linked to many hallmarks of aging.

Quantifying the Decline

Multiple studies have measured NAD+ concentrations in human tissues across different age groups. Research published by Massudi et al. (2012) in PLOS ONE found that NAD+ levels in human skin tissue decreased steadily with age, with levels in subjects over 60 being significantly lower than those in younger cohorts.

Subsequent work by Imai and Guarente (2014), published in Trends in Cell Biology, proposed a systemic model of NAD+ decline. They described how reduced NAD+ biosynthesis in the hypothalamus may trigger a cascade of age-related dysfunction across multiple organ systems, including the brain, vasculature, liver, muscle, and adipose tissue.

Why NAD+ Falls: The Mechanisms

NAD+ decline is driven by at least two well-characterised mechanisms. First, the activity of CD38 — a NAD+-consuming enzyme — increases with age and chronic inflammation. Camacho-Pereira et al. (2016), writing in Cell Metabolism, demonstrated that CD38 expression rises dramatically in aged tissues and is a major contributor to age-related NAD+ depletion.

Second, the salvage pathway — the primary route by which cells recycle and regenerate NAD+ — becomes less efficient over time. The rate-limiting enzyme in this pathway, NAMPT (nicotinamide phosphoribosyltransferase), shows reduced expression in aged tissues, further compounding the deficit.

Downstream Consequences

Depleted NAD+ levels have been linked to impairments across virtually every hallmark of aging. Research by Yoshino, Baur, and Imai (2018) in Cell Metabolism provided a comprehensive review connecting NAD+ decline to:

• Mitochondrial dysfunction and reduced ATP production
• Impaired DNA repair via PARP1 hyper-activation
• Reduced sirtuin activity, compromising gene silencing and metabolic regulation
• Increased susceptibility to metabolic diseases including type 2 diabetes
• Neurodegeneration and cognitive decline
• Chronic low-grade inflammation (inflammaging)

Restoring NAD+: The Precursor Approach

Given that direct NAD+ supplementation faces bioavailability challenges (the molecule is large and rapidly degraded in the gut), researchers have focused on NAD+ precursors. NMN (nicotinamide mononucleotide) has emerged as a leading candidate due to its position as the direct substrate for NMNAT enzymes in the salvage pathway.

Mills et al. (2016), in a landmark study published in Cell Metabolism, demonstrated that long-term NMN administration in mice reversed virtually all age-associated physiological decline, including improvements in energy metabolism, lipid profiles, insulin sensitivity, and physical activity levels — without any observed toxicity.

Clinical Relevance

While the majority of mechanistic research has been conducted in animal models, several human clinical trials have now confirmed that NMN supplementation safely elevates blood NAD+ levels. A randomised, double-blind, placebo-controlled trial by Yi et al. (2023), published in GeroScience, found that oral NMN supplementation (300 mg and 600 mg daily) significantly increased blood NAD+ concentrations in middle-aged adults after 60 days, with improvements in walking endurance and arterial stiffness.